Srdan Verstovsek

Srdan Verstovsek is the world's leading clinical investigator in myelofibrosis who led the pivotal COMFORT-I trial establishing ruxolitinib as the first approved therapy for myelofibrosis. His research has defined the clinical benefit of JAK inhibition in terms of splenomegaly reduction, symptom improvement, and overall survival in myelofibrosis. He has subsequently led trials of multiple next-generation JAK inhibitors and combination strategies. His work transformed the treatment landscape for patients with this historically difficult-to-treat myeloid malignancy.